New Review Maps Kratom’s Cardiovascular Risks and Drug-Interaction Concerns

Why it matters

Clinicians may need to ask about kratom when evaluating unexplained tachycardia, QT prolongation, arrhythmia, or medication interactions.

The big picture

The review synthesizes experimental and clinical evidence on mitragynine and 7-hydroxymitragynine. It emphasizes that product variability, polysubstance exposure, and reliance on case reports make risk estimates uncertain.

Key findings

• Reported manifestations include tachycardia, hypertension, QTc prolongation, Brugada-pattern ECG changes, ventricular arrhythmias, and cardiac arrest.\nLaboratory studies suggest effects on cardiac potassium and sodium channels.\nKratom may inhibit CYP450 enzymes and transporters involved in cardiovascular drug exposure.\nThe authors call for prospective studies using standardized preparations.

What they say

The authors state that greater clinical awareness and prospective research using standardized kratom preparations are needed to clarify cardiovascular risks and clinically relevant interactions.

Bottom line

**Kratom’s cardiovascular effects remain incompletely defined, but reported arrhythmias and potential drug interactions warrant clinical attention.**